Drugs / non-immunogenic staphylokinase
non-immunogenic staphylokinase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07324837 | Jun 2026 → Nov 2028 expected | ischemic stroke | Supergene, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | non-immunogenic staphylokinase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07324837 ↗ |
| Modality | Protein / enzyme biologic | “recombinant non-immunogenic staphylokinase” NCT07324837 ↗ |
| Route | Intravenous | “single intravenous bolus” NCT07324837 ↗ |